Therapeutic Implications of PPARγ in Human Osteosarcoma
Osteosarcoma (OS) is the most common nonhematologic malignancy of bone in children and adults. Although dysregulation of tumor suppressor genes and oncogenes, such as Rb, p53, and the genes critical to cell cycle control, genetic stability, and apoptosis have been identified in OS, consensus genetic...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2010-01-01
|
| Series: | PPAR Research |
| Online Access: | http://dx.doi.org/10.1155/2010/956427 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832554452476755968 |
|---|---|
| author | Eric R. Wagner Bai-Cheng He Liang Chen Guo-Wei Zuo Wenli Zhang Qiong Shi Qing Luo Xiaoji Luo Bo Liu Jinyong Luo Farbod Rastegar Connie J. He Yawen Hu Barrett Boody Hue H. Luu Tong-Chuan He Zhong-Liang Deng Rex C. Haydon |
| author_facet | Eric R. Wagner Bai-Cheng He Liang Chen Guo-Wei Zuo Wenli Zhang Qiong Shi Qing Luo Xiaoji Luo Bo Liu Jinyong Luo Farbod Rastegar Connie J. He Yawen Hu Barrett Boody Hue H. Luu Tong-Chuan He Zhong-Liang Deng Rex C. Haydon |
| author_sort | Eric R. Wagner |
| collection | DOAJ |
| description | Osteosarcoma (OS) is the most common nonhematologic malignancy of bone in children and adults. Although dysregulation of tumor suppressor genes and oncogenes, such as Rb, p53, and the genes critical to cell cycle control, genetic stability, and apoptosis have been identified in OS, consensus genetic changes that lead to OS development are poorly understood. Disruption of the osteogenic differentiation pathway may be at least in part responsible for OS tumorigenesis. Current OS management involves chemotherapy and surgery. Peroxisome proliferator-activated receptor (PPAR) agonists and/or retinoids can inhibit OS proliferation and induce apoptosis and may inhibit OS growth by promoting osteoblastic terminal differentiation. Thus, safe and effective PPAR agonists and/or retinoid derivatives can be then used as adjuvant therapeutic drugs for OS therapy. Furthermore, these agents have the potential to be used as chemopreventive agents for the OS patients who undergo the resection of the primary bone tumors in order to prevent local recurrence and/or distal pulmonary metastasis. |
| format | Article |
| id | doaj-art-c0cc2d40f3d6432e987ab30af7dab4fe |
| institution | Kabale University |
| issn | 1687-4757 1687-4765 |
| language | English |
| publishDate | 2010-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | PPAR Research |
| spelling | doaj-art-c0cc2d40f3d6432e987ab30af7dab4fe2025-02-03T05:51:26ZengWileyPPAR Research1687-47571687-47652010-01-01201010.1155/2010/956427956427Therapeutic Implications of PPARγ in Human OsteosarcomaEric R. Wagner0Bai-Cheng He1Liang Chen2Guo-Wei Zuo3Wenli Zhang4Qiong Shi5Qing Luo6Xiaoji Luo7Bo Liu8Jinyong Luo9Farbod Rastegar10Connie J. He11Yawen Hu12Barrett Boody13Hue H. Luu14Tong-Chuan He15Zhong-Liang Deng16Rex C. Haydon17Molecular Oncology Laboratory, Department of Surgery, The University of Chicago Medical Center, Chicago, IL 60637, USAMolecular Oncology Laboratory, Department of Surgery, The University of Chicago Medical Center, Chicago, IL 60637, USAMolecular Oncology Laboratory, Department of Surgery, The University of Chicago Medical Center, Chicago, IL 60637, USAMolecular Oncology Laboratory, Department of Surgery, The University of Chicago Medical Center, Chicago, IL 60637, USAMolecular Oncology Laboratory, Department of Surgery, The University of Chicago Medical Center, Chicago, IL 60637, USAMolecular Oncology Laboratory, Department of Surgery, The University of Chicago Medical Center, Chicago, IL 60637, USAMolecular Oncology Laboratory, Department of Surgery, The University of Chicago Medical Center, Chicago, IL 60637, USAMolecular Oncology Laboratory, Department of Surgery, The University of Chicago Medical Center, Chicago, IL 60637, USAMolecular Oncology Laboratory, Department of Surgery, The University of Chicago Medical Center, Chicago, IL 60637, USAMolecular Oncology Laboratory, Department of Surgery, The University of Chicago Medical Center, Chicago, IL 60637, USAMolecular Oncology Laboratory, Department of Surgery, The University of Chicago Medical Center, Chicago, IL 60637, USAMolecular Oncology Laboratory, Department of Surgery, The University of Chicago Medical Center, Chicago, IL 60637, USAMolecular Oncology Laboratory, Department of Surgery, The University of Chicago Medical Center, Chicago, IL 60637, USAMolecular Oncology Laboratory, Department of Surgery, The University of Chicago Medical Center, Chicago, IL 60637, USAMolecular Oncology Laboratory, Department of Surgery, The University of Chicago Medical Center, Chicago, IL 60637, USAMolecular Oncology Laboratory, Department of Surgery, The University of Chicago Medical Center, Chicago, IL 60637, USAMolecular Oncology Laboratory, Department of Surgery, The University of Chicago Medical Center, Chicago, IL 60637, USAMolecular Oncology Laboratory, Department of Surgery, The University of Chicago Medical Center, Chicago, IL 60637, USAOsteosarcoma (OS) is the most common nonhematologic malignancy of bone in children and adults. Although dysregulation of tumor suppressor genes and oncogenes, such as Rb, p53, and the genes critical to cell cycle control, genetic stability, and apoptosis have been identified in OS, consensus genetic changes that lead to OS development are poorly understood. Disruption of the osteogenic differentiation pathway may be at least in part responsible for OS tumorigenesis. Current OS management involves chemotherapy and surgery. Peroxisome proliferator-activated receptor (PPAR) agonists and/or retinoids can inhibit OS proliferation and induce apoptosis and may inhibit OS growth by promoting osteoblastic terminal differentiation. Thus, safe and effective PPAR agonists and/or retinoid derivatives can be then used as adjuvant therapeutic drugs for OS therapy. Furthermore, these agents have the potential to be used as chemopreventive agents for the OS patients who undergo the resection of the primary bone tumors in order to prevent local recurrence and/or distal pulmonary metastasis.http://dx.doi.org/10.1155/2010/956427 |
| spellingShingle | Eric R. Wagner Bai-Cheng He Liang Chen Guo-Wei Zuo Wenli Zhang Qiong Shi Qing Luo Xiaoji Luo Bo Liu Jinyong Luo Farbod Rastegar Connie J. He Yawen Hu Barrett Boody Hue H. Luu Tong-Chuan He Zhong-Liang Deng Rex C. Haydon Therapeutic Implications of PPARγ in Human Osteosarcoma PPAR Research |
| title | Therapeutic Implications of PPARγ in Human Osteosarcoma |
| title_full | Therapeutic Implications of PPARγ in Human Osteosarcoma |
| title_fullStr | Therapeutic Implications of PPARγ in Human Osteosarcoma |
| title_full_unstemmed | Therapeutic Implications of PPARγ in Human Osteosarcoma |
| title_short | Therapeutic Implications of PPARγ in Human Osteosarcoma |
| title_sort | therapeutic implications of pparγ in human osteosarcoma |
| url | http://dx.doi.org/10.1155/2010/956427 |
| work_keys_str_mv | AT ericrwagner therapeuticimplicationsofpparginhumanosteosarcoma AT baichenghe therapeuticimplicationsofpparginhumanosteosarcoma AT liangchen therapeuticimplicationsofpparginhumanosteosarcoma AT guoweizuo therapeuticimplicationsofpparginhumanosteosarcoma AT wenlizhang therapeuticimplicationsofpparginhumanosteosarcoma AT qiongshi therapeuticimplicationsofpparginhumanosteosarcoma AT qingluo therapeuticimplicationsofpparginhumanosteosarcoma AT xiaojiluo therapeuticimplicationsofpparginhumanosteosarcoma AT boliu therapeuticimplicationsofpparginhumanosteosarcoma AT jinyongluo therapeuticimplicationsofpparginhumanosteosarcoma AT farbodrastegar therapeuticimplicationsofpparginhumanosteosarcoma AT conniejhe therapeuticimplicationsofpparginhumanosteosarcoma AT yawenhu therapeuticimplicationsofpparginhumanosteosarcoma AT barrettboody therapeuticimplicationsofpparginhumanosteosarcoma AT huehluu therapeuticimplicationsofpparginhumanosteosarcoma AT tongchuanhe therapeuticimplicationsofpparginhumanosteosarcoma AT zhongliangdeng therapeuticimplicationsofpparginhumanosteosarcoma AT rexchaydon therapeuticimplicationsofpparginhumanosteosarcoma |